Connect with us

Hi, what are you looking for?


FET, INJ soar up to 20% as Injective announces plans to collaborate with

Injective Price Skyrockets (FET) and Injective (INJ) defied the current bearish markets with significant price increases over the past day.

Monday’s X post from Injective about “something brewing” with catalyzed recoveries for the altcoins within the last 24 hours.

Injective’s post feature the company’s logos with a wavy line connecting them. That indicates an exchange of data between the duo.

Despite the few details, crypto enthusiasts interpreted the image as signaling a strategic partnership between Injective and

Market response

While the community awaits further details on the planned alliance, Injective’s post attracted speculations.

The development comes as players await the upcoming merger between, Ocean Protocol, and SingularityNET, into the ASI token.

One player questioned whether FET developers have shifted from the anticipated ASI token merger and opted to work with Injective.

FET and INJ’s current price actions

The speculations that emerged saw the associated tokens recovering from Monday’s slump.

FET climbed to $1.70 from $1.42 following the Injective’s post, gaining 19.72% on its daily chart. traded at $1.67 at press time, with daily trading volume up 85% to $282.5 million.

Altcoin INJ displayed a similar performance as it gained 14.59% over the last 24 hours to trade at $23.11 during this writing.

FET & INJ 1D Charts on Coinmarketcap

Besides the Injective-induced recovery, AI-related tokens such as AGIX, ARKM, and OCEAN recorded bullish moves over the past week.

AGIX gained 37% on its 7-day chart, while ARKM and OCEAN soared 28% and 35% in that timeframe.

The performance likely drew attention as the broad market recorded losses over the last seven days.

Bitcoin and Ethereum dropped 6.5% and 1.25% in the past week.

AGIX, FET, and OCEAN have stayed on the investor radar due to the upcoming merger, potentially contributing to their upside stance.

The trio looks ready to maintain robust momentum in the upcoming sessions.

Analyst Posty displayed confidence in FET’s recovery as “the chart isn’t looking too bad.” printed a higher low, and Posty expects a smooth sail toward $1.95 if FET overcomes the resistance zone at $1.70.

Further, Injective’s staking data shows confidence about the altcoin’s future performance.

INJ investors have staked more than 58.44 million tokens, painting an optimistic picture for the token.

Bitcoin’s recovery from its current downbeat mood will boost FET and INJ’s revivals to record highs.

The post FET, INJ soar up to 20% as Injective announces plans to collaborate with appeared first on Invezz

You May Also Like

Editor's Pick

In Risky Business: Why Insurance Markets Fail and What to Do About It (Yale University Press, 2023), economists Liran Einav (Stanford), Amy Finkelstein (MIT),...

Editor's Pick

If you haven’t been following the “Twitter Files” saga, the gist of it is that the US federal government routinely pressured pre-Musk Twitter, and...

Editor's Pick

On April 23, 1985, the Coca-Cola Company made one of the biggest mistakes in American business history: it changed the formula for Coca-Cola. Outraged...

Editor's Pick

For years the North Korean playbook was obvious to the world. The Democratic People’s Republic of Korea wanted to be the center of attention....

Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2023